Hypera S.A. · Healthcare
$20.50
-53.4%
Jun 17, 2026
C
MarginalGraded against HYPE3's own history at this drawdown — not the market's.
What it means: HYPE3's own history does not strongly favor buying at this level yet.
What to do: Consider watching and waiting for a deeper dip or a higher grade.
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Pol
Three plain-English paragraphs — current state, historical base rate, and interpretation — so you walk away with context, not a dashboard.
In plain terms: HYPE3 is 53.4% below its highest-ever price. Dipsern checks every past time it was this far down and grades how the next 90 days usually went.
Hypera SA (HYPE3) sits 53.4% off its peak and is currently in a severe drawdown, last printing at $20.5. A 35-60% drawdown is the territory where most retail investors capitulate. It's also where the highest-probability historical entries have clustered for resilient assets.
HYPE3 reaches this drawdown band repeatedly in its history (117 observations), which is a meaningful sample for the segmentation engine to compute a stable median forward return. The engine uses a rolling 90-day window and gives more weight to recent years — this lets the signal adapt to regime changes (e.g., post-COVID volatility) without losing the long-run base rate.
Drawdown-based signals work across asset classes but the magnitude of meaningful moves varies. Dipsern computes the segmentation per-asset so the bands are calibrated to HYPE3's own volatility history. Severe drawdowns are where Dipsern's segmentation provides the most edge: ordinary base rates don't apply, but the asset's own history at this exact depth does. The forward-return distribution here is bimodal — either rapid recovery or continued decline.
Five tickers closest to HYPE3's distance from all-time high. Same category, one tap away.
Dipsern segments the full drawdown range into 20 equal-width bands. The table shows the number of confirmed historical observations in each band for HYPE3. Median forward returns, win rates, and prediction errors are available in the full analysis.
We segment 40+ years of HYPE3's price history into 20 equal-width drawdown bands and compute forward median returns, win rates, and prediction error per band. No look-ahead bias. Pure NumPy. Open math, gated numbers.
Years of history
40+
Drawdown bands
20
Look-ahead bias
None
Data sources
4
See the Dipsern grade, median returns, win rates, prediction accuracy, 8 interactive charts, historical price paths, and a plain-English verdict for HYPE3.
Dipsern is research and a second opinion — not a broker. You'd buy HYPE3 at your own broker.
Analyze HYPE3 FreeNo credit card required · 5 free analyses per month
Signal computed Jun 17, 2026 using default parameters (90-day return period, 20 segments, 0.95 decay). Data sourced from Yahoo Finance, Binance, CoinGecko, and Steam Market.